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Abstract 
Background  Asian population are at increased risk of bleeding during the warfarin treatment, so the recommended optimal interna-
tional normalized ratio (INR) level may be lower in Asians than in Westerners. The aim of this prospective multicenter study was to deter-
mine the optimal INR level in Thai patients with non-valvular atrial fibrillation (NVAF). Methods  Patients with NVAF who were on war-
farin for stroke prevention were recruited from 27 hospitals in the nationwide COOL-AF registry in Thailand. We collected demographic data, 
medical history, risk factors for stroke and bleeding, concomitant disease, electrocardiogram and laboratory data including INR and anti-
thrombotic medications. Outcome measurements included ischemic stroke/transient ischemic attack (TIA) and major bleeding. Optimal INR 
level was assessed by the calculation of incidence density for six INR ranges (< 1.5, 1.5–1.99, 2–2.49, 2.5–2.99, 3–3.49, and ≥ 3.5). Results  
A total of 2,232 patients were included. The mean age of patients was 68.5 ± 10.6 years. The mean follow-up duration was 25.7 ± 10.6 
months. There were 63 ischemic stroke/TIA and 112 major bleeding events. The lowest prevalence of ischemic stroke/TIA and major bleed-
ing events occurred within the INR range of 2.0–2.99 for patients < 70 years and 1.5–2.99 for patients ≥ 70 years. Conclusions  The INR 
range associated with the lowest risk of ischemic stroke/TIA and bleeding in the Thai population was 2.0–2.99 for patients < 70 years and 
1.5–2.99 for patients ≥ 70 years. The rates of major bleeding and ischemic stroke/TIA were both higher than the rates reported in Western 
population. 
J Geriatr Cardiol 2020; 17: 612620. doi:10.11909/j.issn.1671-5411.2020.10.004 
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1  Introduction 
The prevalence of non-valvular atrial fibrillation (NVAF) 
is approximately 1% in the general population.[1,2] However, 
that rate increases up to approximately 9% among patients 
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aged older than 80 years.[1] Due to the large size of Asian 
population and the increasing proportion of elderly popula-
tion, it is estimated that approximately 49 million men and 
23 million women will be affected by NVAF by 2050.[2] It 
is estimated that the risk of ischemic stroke in patients with 
NVAF is approximately 5% per year or five times the risk 
in general population.[1] 
Oral anticoagulant is generally recommended for the 
prevention of ischemic stroke in patients with one or more 
stroke risk factors.[3] Recent practice guidelines recommend 
non-vitamin K antagonist anticoagulant (NOAC) over war-
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farin for stroke prevention in NVAF due to its relative effi-
cacy, safety and convenience compared to warfarin.[3–6] 
However, in many Asian countries and in many developing 
countries, warfarin is still the most commonly used oral an-
ticoagulant for stroke prevention in patients with NVAF.[7,8] 
The use of these drugs is still comparatively low due to the 
fear of bleeding and misconception or misunderstanding 
about this drug class.[7] 
In Thailand, NOAC has not been proven to be more cost 
effective than warfarin because the willingness of to pay 
level in the Thai population is lower than in Western coun-
tries.[9] Also, the Asian population has an increased risk of 
bleeding, especially intracranial hemorrhage (ICH), com-
pared to Caucasians, and this increased risk could 4-fold 
higher with warfarin use.[10] The recent NOAC trials also 
demonstrated an increased risk of bleeding in the Asian 
population compared to Caucasians among the patients 
randomized to warfarin treatment.[11] Current guidelines 
recommend that patients on warfarin should have an inter-
national normalized ratio (INR) of 2–3, and that the time in 
therapeutic range (TTR) should be more than 70%;[3,12] 
however, most patients with NVAF in many Asian coun-
tries have a TTR of less than 70% – even in controlled set-
tings, such as clinical trials.[13] Due to a fear of bleeding, 
certain guidelines from Asia recommend a target INR of 
lower than 2–3, especially amongst elderly patients where a 
target INR range of 1.6–2.6 is recommended.[14] Results 
from one study in Chinese population also suggested a lower 
INR target may be needed.[15] 
In this study, we aimed to determine the optimal INR 
target in elderly and non-elderly Thai population with NVAF 
in a prospective multicenter registry, the cohort of antithrom-
botic use and optimal INR level in patients with NVAF in 
Thailand (COOL-AF) registry. 
2  Methods 
2.1  Study population 
We enrolled patients who were 18 years of age or more 
with a diagnosis of NVAF. There were 27 university hospi-
tals, regional hospitals, or general hospitals from all five 
regions of Thailand that participated in this study. The study 
protocol was approved by the Institutional Review Board 
(IRB) of each participating hospital. For hospitals that are 
under the Thailand Ministry of Public Health (MOPH), the 
study protocol was approved by the IRB of the MOPH. All 
patients provided written informed consent prior to partici-
pation. Patients were excluded if they had one or more of 
the following conditions: (1) ischemic stroke within three 
months; (2) prosthetic valve, valve repair, rheumatic valve 
disease, or significant valve disease; (3) thrombocytopenia 
(< 100,000/mm3), myeloproliferative disorders; (4) atrial 
fibrillation (AF) from transient reversible cause (e.g., during 
respiratory tract infection); (5) life expectancy less than 
three years; (6) pregnancy; (7) inability to provide follow-up 
data; (8) refusal to participate in the study; and/or (9) current 
hospitalization or hospitalization within one month prior to 
enrollment. To determine optimal INR levels by incidence 
density analysis, we included only patients who were on 
warfarin and who had at least two INR tests. 
2.2  Study protocol 
After written informed was obtained, data were retrieved 
from medical records and patient interview by the study 
team at each hospital. Data were recorded in a case record 
form (CRF), and then the study team uploaded that data into 
a web-based system. The CRF for each patient was mailed 
to the central data management site. Research staff at the 
central site verified the accuracy and completeness of the 
data between the data on the CRF and the data entered into 
the data management system. Any data-related questions by 
the data management team at the central site were for-
warded to the study team at that enrollment site. After data 
were determined to be accurate and complete, those data 
were locked. Site monitoring was performed at every study 
site to ensure compliance with the study protocol and to 
ensure the collection and recording of consistently accurate 
and high-quality data. 
The study staff at each center was tasked with collecting 
and recording data every six months from medical records 
and telephone interview during follow-up until three years. 
Data relating to cardiovascular events, vital signs, laboratory 
results, and medications were collected at each follow-up 
visit. All data collected during the study period was re-
corded on a CRF with subsequent transfer of that data into 
the web-based system. 
2.3  Data collection and outcome measurement 
The following data were collected: demographic data, 
risk factors for ischemic stroke/transient ischemic attack 
(TIA) and bleeding as listed in the CHA2DS2-VASc and 
HAS-BLED score, medical history, types and duration of AF, 
antithrombotic medications, laboratory (including every INR), 
and 12-lead electrocardiogram data. Each component of the 
CHA2DS2-VASc score was scored and recorded, as follows: 
C = congestive heart failure (1 point); H = hypertension (1 
point); A = age > 75 years (2 points); D = diabetes (1 point); 
S = stroke (2 points); V = vascular disease (1 point); A = age 
65–74 (1 point); and Sc = female sex category (1 point). Each 
component of the HAS-BLED score was scored and re-
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corded, as follows: uncontrolled Hypertension, Abnormal 
renal, or liver function; history of Stroke; history of Bleed-
ing; Labile INR; Elderly (age above 65 years); and Drugs or 
alcohol (all 1 point each). 
The main outcomes during the follow-up were ischemic 
stroke or TIA and major bleeding event. We also collected 
data for minor bleeding. Any main outcome events and their 
related data were recorded and reported according to the 
previously described data reporting process. All events were 
evaluated and verified by the adjudication committee. Any 
questions or concerns raised by the adjudication committee 
were forwarded to the study team at that site for explanation 
or clarification. 
INR level was classified into the following six groups for 
analysis: < 1.5, 1.5–1.99, 2–2.49, 2.5–2.99, 3–3.49, and ≥ 
3.5. INR-specific incidence density was calculated as the 
ratio of the number of thromboembolic or bleeding events 
that occurred in each INR group to the total amount of time 
(patient-years) that each patient stayed in each INR group, 
according to the method described by Rosendaal, et al.[16] in 
1993. Assignment of an event to an INR group was made 
using the first INR during the event or the most recent INR 
level within seven days prior to the occurrence of the 
thromboembolic or bleeding event. 
The time that each patient stayed in each INR group was 
calculated by taking the duration between when a patient 
was in one INR group to when that same patient had an INR 
score that was in another INR group. That total duration was 
then divided in half, and half of the time was allocated to the 
prior INR group and the other half of the time was allocated 
to the new INR group. For example, if a patient had an INR 
of 2.1 that became 2.6 twelve weeks later, the time in the 
2.0–2.49 INR group was six weeks, and the time in the 
2.5–2.99 INR group was six weeks. In order to have been 
included in this analysis, patients had to have at least two 
INR tests. 
Ischemic stroke was defined as sudden-onset neurologic 
deficit lasting greater than 24 hours. TIA was similarly de-
fined, except the duration of the neurologic deficit had to 
have been less than 24 hours. Major bleeding was defined 
using criteria published by the International Society of 
Thrombosis and Haemostasis,[17] which includes: (1) fatal 
bleeding; (2) bleeding in critical area or organs; or (3) 
bleeding that results in a decrease in hemoglobin level of 20 
g/L or more, or that requires a transfusion of two units of 
red cells or more. 
Among patients who died, if the death was related to 
ischemic stroke, we counted this event as an ischemic stroke. 
If, however, the death was related to severe bleeding, we 
counted this a major bleeding event. Deaths that were not 
related to either ischemic stroke or severe bleeding were not 
included in either main outcome category. Main outcome 
events were further subcategorized, as follows: fatal or 
non-fatal stroke, and fatal and non-fatal major bleeding. 
2.4  Statistical analysis 
SPSS Statistics version 23.0 (SPSS, Inc., Chicago, IL, 
USA) was used for all statistical analyses. Categorical data, 
such as gender and comorbid diseases, are presented as fre-
quency and percentage. Continuous variables, such as age, 
are expressed as mean ± SD. The optimal INR level was 
determined by comparing the incidence density among all 
six INR groups. In this study, for the purpose of comparison 
with previous data in Asian population,[14,18] we defined 
patients older or equal to 70 years as elderly. The incidence 
density of thromboembolic and bleeding complications was 
compared using Pearson’s chi-square test. The optimal INR 
level was defined as the lowest incidence density of throm-
boembolic or hemorrhagic complications. Concerning the 
comparison of repeated measure INR data, since the number 
of INR tests during follow-up varied among the study popu-
lation, repeated measures analysis of variance (ANOVA) 
was judged not to be suitable for this analysis. Alternatively, 
linear mixed model (fixed effect) was selected to compare 
the repeated measurement INR level-related outcome 
measures at time. A P-value less than 0.05 was considered 
as being statistically significant for all tests. 
3  Results 
There was a total of 3,461 patients with NVAF enrolled 
in the main study. Warfarin was used in 2,375 patients 
(68.6%). After excluding 143 patients with less than two 
available INR tests during the follow-up, 2,322 patients 
remained for inclusion into this ‘optimal INR’ analysis 
(Figure 1). The average age of patients was 68.5 ± 10.6 
years, and 56% were male. Baseline characteristics are  
 
Figure 1.  Flowchart describing the patient recruitment proc-
ess. INR: international normalized ratio; NVAF: non-valvular atrial 
fibrillation. 
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Table 1.  Baseline characteristics of the study population. 
Characteristics All (n = 2,232) 
Age, yrs 68.5 ± 10.6 
Male gender 1,251 (56.0%) 
Time after diagnosis of atrial fibrillation, yrs 3.6 ± 4.4 
Atrial fibrillation  
Paroxysmal 631 (28.3%) 
Persistent 421 (18.9%) 
Permanent 1,180 (52.9%) 
History of heart failure 626 (28.0%) 
History of coronary artery disease 356 (15.9%) 
Devices 216 (9.7%) 
History of ischemic stroke/TIA 485 (21.7%) 
Hypertension 1,639 (73.4%) 
Diabetes mellitus 609 (27.3%) 
History of bleeding 241 (10.8%) 
CHA2DS2-VASc score  
0 (male), 1 (female) (low risk) 76 (3.4%) 
1 (male), 2 (female) (intermediate risk) 294 (13.2%) 
≥ 2 (male), ≥ 3 (female) (high risk) 1,862 (83.4%) 
HAS-BLED score  
0 269 (12.1%) 
12 1,579 (70.7%) 
≥ 3 384 (17.2%) 
Data are presented as means ± SD or n (%). TIA: transient ischemic attack. 
 
shown in Table 1. The average CHA2DS2-VASc and HAS- 
BLED score was 3.3 ± 1.6 and 1.6 ± 1.0, respectively. Ac-
cording to the requirement of this analysis, all patients were 
on warfarin. Antiplatelet therapy was used in 277 patients 
(12.4%), mostly aspirin. 
The average follow-up time was 25.7 ± 10.6 months, and 
patients were followed-up for 4,786 patient-years. Table 2 
demonstrates the rate of ischemic stroke/TIA and bleeding 
events, including ICH. There was a total of 63 ischemic 
stroke/TIA (1.64 per 100 patient-years) in 59 patients, and 
112 major bleeding events (2.92 per 100 patient-years) in 
104 patients. The overall rate of ischemic stroke/TIA, major 
bleeding, and ICH was 1.64, 2.92, and 0.76 per 100 per-
son-years, respectively. Although the majority of cases with 
ischemic stroke/TIA or major bleeding were non-fatal, the 
fatality rate among patients with ICH was 37.9%. 
The risk of ischemic stroke/TIA increased as the INR 
level decreased, and the risk of major bleeding increased as 
the INR level increased (Table 3 & Figure 2). Figure 2B 
shows the combined rate of ischemic stroke/TIA and major 
bleeding to be lowest when the INR was within the range of 
2–2.99. There was no significant difference in this com-
bined incidence rate for INR ranges 2–2.49 and 2.5–2.99. 
The combined event incidence rate was increased when the 
INR was below 2.0, and when the INR was 3.0 or greater, 
especially at the high and low extremes of INR level. 
Ischemic stroke/TIA rate increased twice for INR 1.5–1.99 
compared to 2.0–2.49 and major bleeding rate increased 
almost three times when INR 3–3.49 compared to 2.5–2.99. 
This is especially true for patients younger than 70 years as 
shown in Table 3. The incidence rate of ischemic stroke/ 
TIA markedly increased when the INR less than 1.5, whereas 
the incidence rate of major bleeding markedly increased 
when the INR more than 3.0 in patients ≥ 70 years as com-
pared to those < 70 years. For patients < 70 years, the inci-
dence rate of ischemic stroke/TIA increased from 0.49 to 
1.64 per 100 person-years when for INR 2.0–2.49 compared 
to INR 1.5–1.99, whereas the incidence rate of major 
bleeding was similar (0.66 to 0.82 per 100 person-years). 
For patients ≥ 70 years, the incidence rate of ischemic 
stroke/TIA increased from 1.42 to 1.94 per 100 person- 
years when for INR 2.0–2.49 compared to INR 1.5–1.99, 
whereas the incidence rate of major bleeding decreased 
from 2.30 to 1.45 per 100 person-years. The incidence rate  
Table 2.  Ischemic stroke/TIA and bleeding events documented during the follow-up period. 
Events Number of patients Number of events Per 100 person-years 
Total ischemic stroke/TIA 59 (2.6%) 63 (2.8%) 1.64 (2.413.52) 
Fatal ischemic stroke/TIA 9 (0.4%) 9 (0.4%) 0.23 (0.110.45) 
Non-fatal ischemic stroke/TIA 50 (2.2%) 54 (2.4%) 1.41 (1.061.84) 
Total major bleeding 104 (4.7%) 112 (5.0%) 2.92 (1.262.10) 
Fatal major bleeding 15 (0.7%) 15 (0.7%) 0.39 (0.220.65) 
Non-fatal major bleeding 89 (4.0%) 97 (4.3%) 2.53 (2.053.09) 
Total ICH 28 (1.3%) 29 (1.3%) 0.76 (0.511.09) 
Fatal ICH 11 (0.5%) 11 (0.5%) 0.29 (0.140.51) 
Non-fatal ICH 17 (0.8%) 18 (0.8%) 0.47 (0.280.74) 
Minor bleeding 330 (14.8%) 478 (21.4%) 12.47 (11.3813.64) 
Other death 101 (4.5%) 101 (4.5%) 2.64 (2.153.20) 
ICH: intracranial hemorrhage; TIA: transient ischemic attack. 
616 Krittayaphong R, et al. Optimal INR level in Thai AF 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
Table 3.  Rates of ischemic stroke/TIA and bleeding events during follow-up stratified by INR level. 
 Ischemic stroke/TIA and bleeding events (per 100 person-years) 
INR level 
 Ischemic stroke/TIA Major bleeding Minor bleeding Total bleeding 
Ischemic stroke/TIA or 
major bleeding 
All (n = 2,232)       
< 1.5  6.63 (4.419.59) 1.18 (0.382.77) 11.37 (8.3915.08) 12.56 (9.4116.43) 7.82 (5.3810.98) 
1.52  1.78 (1.022.88) 1.11 (0.532.04) 10.88 (8.8313.26) 11.99 (9.8314.47) 2.89 (1.894.23) 
22.5  0.94 (0.471.68) 1.45 (0.842.32) 8.35 (6.7810.18) 9.80 (8.0911.77) 2.39 (1.593.45) 
2.53  0.68 (0.221.59) 1.50 (0.752.68) 10.89 (8.6313.55) 12.39 (9.9715.20) 2.18 (1.243.54) 
33.5  0.61 (0.072.21) 4.28 (2.347.18) 15.91 (11.8820.85) 20.19 (15.6125.68) 4.90 (2.807.95) 
> 3.5  0.36 (0.012.03) 20.03 (15.0726.03) 37.14 (30.2445.03) 57.17 (48.5166.75) 20.39 (15.3826.44) 
Total  1.64 (2.413.52) 2.92 (1.262.10) 12.47 (11.3813.64) 15.39 (14.1816.69) 4.57 (3.925.30) 
Age ≥ 70 yrs (n = 1,083)       
< 1.5  10.71 (6.7316.25) 1.95 (0.535.00) 12.18 (7.8918.00) 14.12 (9.4720.32) 12.66 (8.2918.58) 
1.52  1.94 (0.843.82) 1.45 (0.533.16) 11.37 (8.3315.13) 12.82 (9.6116.79) 3.39 (1.855.69) 
22.5  1.42 (0.612.79) 2.30 (1.233.94) 8.33 (6.1211.08) 10.64 (8.1213.69) 3.72 (2.305.69) 
2.53  0.86 (0.182.50) 2.57 (1.184.88) 13.43 (9.8717.86) 16.00 (12.0920.78) 3.43 (1.775.99) 
33.5  0.65 (0.023.59) 4.52 (1.189.31) 18.06 (12.0026.11) 22.58 (15.7331.40) 5.16 (2.2310.17) 
> 3.5  0.71 (0.023.92) 27.54 (19.5337.55) 43.08 (32.8655.18) 70.62 (57.3085.65) 28.25 (20.1238.36) 
Total  2.35 (1.703.17) 4.26 (3.375.32) 13.94 (12.2815.75) 18.20 (16.3020.28) 6.61 (5.497.90) 
Age < 70 yrs (n = 1,149)       
< 1.5  2.77 (1.016.02) 0.46 (0.012.57) 10.61 (6.7215.90) 11.07 (1.0916.46) 3.23 (1.306.65) 
1.52  1.64 (0.713.23) 0.82 (0.222.10) 10.46 (7.7813.74) 11.28 (8.4914.67) 2.46 (1.274.30) 
22.5  0.49 (0.101.44) 0.66 (0.181.68) 8.37 (6.2411.01) 9.03 (6.8011.76) 1.15 (0.462.37) 
2.53  0.52 (0.061.88) 0.52 (0.061.88) 8.58 (5.9012.04) 9.10 (6.3312.64) 1.04 (0.282.66) 
33.5  0.58 (0.013.24) 4.07 (1.648.39) 13.97 (8.9420.76) 18.04 (12.2525.58) 4.66 (2.019.16) 
> 3.5  0 12.03 (6.8819.54) 30.83 (22.1241.82) 42.86 (32.4655.53) 12.03 (6.8819.54) 
Total  1.00 (0.611.54) 1.70 (1.182.37) 11.13 (9.7212.69) 12.83 (11.3114.50) 2.70 (2.033.52) 
INR: international normalized ratio; TIA: transient ischemic attack. 
 
of combined ischemic stroke/TIA and major bleeding in 
patients < 70 years was lowest at INR 2.0–2.99, whereas in 
patients 70 years, it was lowest at INR 1.5–2.99 indicating a 
different target INR for these populations. 
The incidence rate of ischemic stroke/TIA within the 
INR range of 2–2.99 was 0.79 per 100 person-years, which 
is 8.4 times lower than incidence rate of ischemic stroke/ 
TIA when the INR level was < 1.5. The incidence rate of 
major bleeding within the INR range of 2–2.99 was 1.52 per 
100 person-years, which was 12.9 times lower than incidence 
rate of major bleeding when the INR level was ≥ 3.5. Figure 
2 shows a survival graph of ischemic stroke/TIA compared 
with major bleeding (Figure 2A), and of combination of 
ischemic stroke/TIA and major bleeding (Figure 2B) – both 
stratified by INR range/group. Figure 3 demonstrated the 
incidence rate of ischemic stroke/TIA and major bleeding 
among patients ≥ 70 years, < 70 years as well as all patients. 
Linear mixed model analysis was used to determine the 
difference in INR levels between patients with and without 
events considering the effect of repeated measure of INR 
tests. The results, as shown in Table 4, show that the mean 
INR in patients with ischemic stroke/TIA was significantly 
lower than the mean INR among patients without ischemic 
stroke/TIA, and that the mean INR in patients with major or 
minor bleeding was significantly higher than the mean INR 
among patients without major or minor bleeding. 
4  Discussion 
In this large prospective multicenter nationwide registry 
of patients with NVAF, our principal findings was that the 
optimal INR level that was associated with the lowest inci-
dence rate of combined efficacy and safety endpoints 
(ischemic stroke/TIA and major bleeding) was 2–2.99. 
Ischemic stroke/TIA rate increased twice for INR 1.5–1.99 
compared to INR 2.0–2.49 and major bleeding rate in-
creased almost three times when INR 3–3.49 compared to 
INR 2.5–2.99. 
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Figure 2.  Incidence rate of ischemic stroke/TIA compared to 
incidence rate of major bleeding per 100 person-years in each 
INR group (A) and incidence rate of ischemic stroke/TIA and 
major bleeding combined per 100 person-years in each INR 
group (B). INR 2–3 is indicated by the shade area. INR: interna-
tional normalized ratio; TIA: transient ischemic attack. 
 
Figure 3.  Incidence rate of ischemic stroke/TIA (A) and ma-
jor bleeding (B) per 100 person-years in each INR group 
among patients ≥ 70 years, < 70 years as well as all patients. 
INR 2–3 is indicated by the shade area. INR: international normal-
ized ratio; TIA: transient ischemic attack. 
Table 4.  The results of linear mixed model analysis to test the difference of INR levels in patients with and without outcomes based 
on repeated INR data. 
 Mean INR 
Standard error  
of the mean 
Mean difference  
(95% CI) 
Effect estimate 
(Beta) 
Effect standard  
error 
P-value 
Ischemic stroke/TIA 1.79 0.17 0.60 (0.930.28) 0.60 0.17 < 0.001 
No ischemic stroke/TIA 2.40 0.01     
Total bleeding 3.41 0.05 1.05 (0.941.16) 1.05 0.05 < 0.001 
No bleeding 2.37 0.01     
Major bleeding 5.12 0.13 2.74 (2.502.99) 2.74 0.13 < 0.001 
No major bleeding 2.38 0.01     
ICH 2.94 0.25 0.55 (0.061.03) 0.55 0.25 0.028 
No ICH 2.39 0.01     
Minor bleeding 3.02 0.06 0.63 (0.510.75) 0.63 0.06 < 0.001 
No minor bleeding 2.38 0.01     
Follow-up time point    2.45 0.02 < 0.001 
A P-value < 0.05 indicates statistical significance. The interaction effect between thromboembolic, bleeding, minor bleeding, and major bleeding event and time 
was non-significant (P > 0.05). ICH: intracranial hemorrhage; INR: international normalized ratio; TIA: transient ischemic attack. 
 
Warfarin is still used in the majority of patients in many 
Asian countries, especially in low or middle-income coun-
tries, due to its comparatively lower drug costs.[9] It is rec-
ommended that the TTR be greater than 70% in patients 
who use warfarin.[3,12] However, data from one large clinical 
trial revealed a TTRs within the range of 50%–65%,[13] 
which was even worse in real-world clinical settings, espe-
cially among Asian population.[19,20] In general, Asian po-
pulations have a lower TTR compared to Western coun-
tries.[21] For example, the Global Anticoagulant Registry in 
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the Field (GARFIELD) study reported that only 17% of 
Asian population had a TTR > 65% compared to 49% in West-
ern population.[19] Importantly, efficacy and safety outcomes 
are related to the quality of INR control.[19,22] 
Previous data indicated that Asian population had an in-
creased risk of ICH, especially while on warfarin therapy. 
This increased risk of major bleeding and ICH in Asians 
was also evident in the four large clinical trials that com-
pared warfarin with NOACs. Although baseline patient 
characteristics compared between our study and other study, 
such as the GARFIELD registry,[23] are relatively similar, 
the rate of major bleeding in our study (1.64 per 100 per-
son-years) was much higher than the rate reported in the 
GARFIELD registry (0.7% per 100 person-years). Of note, 
the Asian population account for approximately 21% of 
patients in the GARFIELD registry.[21]  
Racial differences in the risk of bleeding may account for 
differences between and among studies. Also, all patients in 
our study were on warfarin and all had NVAF, whereas the 
GARFIELD registry included all types of patients with AF, 
and many used NOACs, which have been associated with a 
lower rate of major bleeding compared to warfarin.[21] 
Major international guidelines recommend a target INR 
within the range of 2.0–3.0, and a TTR of greater than 
70%.[3,5,6] Previous data from a Western population revealed 
the INR range associated with the lowest event rate to be 
2.0–3.0.[24] Ischemic stroke event rates rose steeply at an 
INR level below 2.0; and even at an INR level of 1.7, the 
ischemic stroke rate increased two times compared to the 
rate at INR 2.0.[24] 
These data are at odds with some Japanese and Chinese 
studies. Yamaguchi, et al.[25] compared the clinical out-
comes of low-intensity warfarin (target INR 1.5–2.1) with 
those of the reference group that had a target INR of 2.2–3.5 
among 115 Japanese patients with NVAF; the annual rate of 
ischemic stroke was similar between the two groups, but 
low-intensity warfarin was safer. However, the target INR 
in the reference group was higher compared to the standard 
recommendation of INR 2.0–3.0. Suzuki, et al.[26] studied 
major bleeding rate in 667 patients with NVAF and a target 
INR within the range of 1.6–2.6. They reported a major 
bleeding rate of 2.38%, which is significantly higher than 
the rates reported in Western populations. They also found 
an INR of greater than 2.27 to be an independent predictor 
of major bleeding. Thus, Japanese guidelines for manage-
ment of patients with NVAF recommends an INR target of 
1.6–2.6 in patients older than 70 years of age. This recom-
mendation was based on data from a study by Yasaka, 
et al.,[27] which found the lowest event rates in an elderly 
population occurred when the INR was within the range of  
1.6–2.6. Chen, et al.[15] randomized 786 Chinese patients 
with NVAF into the following three groups: warfarin target 
INR 1.6–2.0, warfarin target INR 2.1–2.6, and aspirin 200 
mg/day, the annual thromboembolic event rate was 2.6%, 
3.1%, and 6.9%, respectively; whereas the major bleeding 
rate was 2.6%, 2.4%, and 0.4%, respectively. The authors 
therefore recommended a target INR within the range of 
1.6–2.5. The results of our study for patients ≥ 70 years and 
< 70 years demonstrated a similar trend as Japanese data.[18] 
We showed that the best INR for the whole group was 
2.0–2.99. The results were more obvious for those younger 
than 70 years. However, for those older than 70 years, the 
acceptable INR would be 1.5–2.99 since the risk of in-
creased major bleeding was more than the benefit for is-
chemic stroke/TIA reduction when compared INR 2.0–2.49 
and INR 1.5–1.99. 
In the present study, among the 2,232 included patients 
with NVAF receiving warfarin therapy, the INR range with 
the lowest combined ischemic stroke/TIA and major bleed-
ing event rate was 2.0–2.99. This finding supports the rec-
ommended target INR levels from major practice guide-
lines.[3,6] Nevertheless, the major bleeding rate in our study 
population was much higher than that reported from West-
ern population.[28] Data from the GARFIELD study showed 
a major bleeding event rate of 0.7 events per 100 person- 
years,[28] which is substantially lower than the 2.9 events per 
100 person-years found in our study using a similar defini-
tion. However, the rate of major bleeding in our study was 
comparable to the rate reported from previous studies in 
Japanese (2.4 events per 100 person-years) and Chinese 
(2.4–2.6 events per 100 person-years) populations.[15,26] The 
rate of ICH in our study was also higher than that seen in 
the GARFIELD study,[28] but was similar to the rate from a 
previous Japanese report.[26] It should also be emphasized 
that a significant proportion of patients who developed ICH 
had an INR less than three prior to the ICH event. Lopes, 
et al.[29] reported that from ARISTOTLE study, 78.5% of 
patients who developed ICH had a pre-ICH INR of less than 
three. Asian population was an independent predictor for 
INR in this study. Data from our study indicated that 62.1% 
of patients who had ICH had a pre-ICH INR of less than 
three. Therefore, the INR within target does not guarantee 
that the patients will be safe from ICH. The ischemic 
stroke/TIA rate in our study was also greater than the rate 
reported from the GARFIELD study. Data from the Fushimi 
AF Registry, which enrolled 3,878 patients with NVAF in 
Japan, also found a higher rate of ischemic stroke and major 
bleeding in Japanese population compared to a Western 
population.[30] 
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4.1  Limitations 
This study is limited by its registry design, and we report 
associations rather than causality. Nonetheless, we have 
recruited subjects from centres nationwide, being represen-
tative of the Thailand population and routine clinical prac-
tice. 
4.2  Conclusions 
The optimal INR level in patients with NVAF in this 
multicenter nationwide study in Thailand was 2.0–2.99 for 
patients < 70 years and 1.5–2.99 for patients ≥ 70 years. The 
rates of major bleeding and ischemic stroke/TIA were both 
higher than the rates reported in Western population. 
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